Dark Day At Idera As Tilsotolimod Fails To ILLUMINATE In Melanoma Study

Prospects Look Bleak

 
• By Kevin Grogan
  
gloomy
Path ahead looks gloomy for tilsotolimod • Source: Shutterstock

More from Clinical Trials

More from R&D